#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	20800	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2604	985.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1681	1681	C	1355	C,T,A	1352,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	20800	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2604	985.1	0	HET	.	.	.	C260T	.	260	260	C	757	757	C	1154	C,T	913,241	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34684	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4085	1058.9	0	.	n	.	0	T695C	SNP	695	695	T	1270	1270	C	1303	C,G,T,A	1300,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34684	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4085	1058.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1912	1912	A	1419	A,T,C	1417,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34684	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4085	1058.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2546	2546	C	1188	C,T,G	1186,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34684	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4085	1058.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3172	3172	T	1195	T,G,C	1190,4,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34684	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4085	1058.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2620	2620	A	1085	A,C	1084,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	3114	folP	852	852	100.0	folP.l15.c17.ctg.1	1797	214.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1165	1167	AGC	337;338;338	A,C;G;C	336,1;338;338	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	8056	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3812	263.4	1	SNP	p	S91F	0	.	.	271	273	TCC	768	770	TCC	293;295;297	T;C,T;C,A	293;294,1;296,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	8056	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3812	263.4	1	SNP	p	D95G	0	.	.	283	285	GAC	780	782	GAC	311;313;315	G;A,G;C	311;311,2;315	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	8056	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3812	263.4	1	SNP	p	D95N	0	.	.	283	285	GAC	780	782	GAC	311;313;315	G;A,G;C	311;311,2;315	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	2920	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1722	210.9	1	SNP	p	G45D	1	.	.	133	135	GAC	718	720	GAC	345;347;345	G,T;A,C;C	343,2;345,2;345	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1612	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	1438	139.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7582	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3426	275.8	1	SNP	p	D86N	0	.	.	256	258	GAC	826	828	GAC	329;328;323	G;A;C,A	329;328;322,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7582	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3426	275.8	1	SNP	p	S87I	0	.	.	259	261	AGT	829	831	AGT	325;330;330	A,T,C;G;T	323,1,1;330;330	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7582	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3426	275.8	1	SNP	p	S87R	0	.	.	259	261	AGT	829	831	AGT	325;330;330	A,T,C;G;T	323,1,1;330;330	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7582	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3426	275.8	1	SNP	p	S87W	0	.	.	259	261	AGT	829	831	AGT	325;330;330	A,T,C;G;T	323,1,1;330;330	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7582	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3426	275.8	1	SNP	p	S88P	0	.	.	262	264	TCC	832	834	TCC	332;333;335	T,G;C,T;C	331,1;332,1;335	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	6226	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3200	242.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1825	1827	GGC	364;366;361	G;G;C,T,G	364;366;359,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1522	1524	GCA	352;352;352	G;C,A;A,C	352;351,1;351,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1525	1527	ATC	350;350;347	A;T,C,G,A;C	350;346,2,1,1;347	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1537	1539	GTG	354;352;352	G;T;G,T,A	354;352;350,1,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1537	1539	GTG	354;352;352	G;T;G,T,A	354;352;350,1,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2041	2043	ACC	304;304;302	A;C;C,T	304;304;301,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2095	2097	GCG	272;272;274	G,T;C,T;G	271,1;270,2;274	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2095	2097	GCG	272;272;274	G,T;C,T;G	271,1;270,2;274	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2218	2220	GGC	306;307;308	G,T;G;C	305,1;307;308	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2227	2229	GGC	312;313;309	G;G;C,T	312;313;308,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2890	250.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2245	2247	CCG	299;297;296	C,G,T;C;G,C	295,3,1;297;295,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	8260	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3393	303.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	4000	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2257	220.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	787	787	C	280	C	280	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	G38E	NONSYN	112	114	GGA	494	496	GAA	361;361;361	G,A;A,C;A	360,1;360,1;361	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	E48G	NONSYN	142	144	GAA	524	526	GGA	335;333;330	G;G,T;A,C	335;332,1;328,2	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	T87A	NONSYN	259	261	ACT	641	643	GCT	333;337;340	G,T;C;T	332,1;337;340	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	647	649	AGC	338;337;343	A;G;C,A	338;337;342,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	739	740	CG	338;337	C,A;G	337,1;337	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	742	744	CAG	334;336;334	C,A;A;G	333,1;336;334	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	746	748	AAA	340;340;337	A;A;A	340;340;337	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	809	811	GAA	349;349;348	G,T;A,C;A	348,1;348,1;348	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	833	835	GCA	349;350;354	G,A;C;A	348,1;350;354	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1016	1018	GAT	368;370;367	G;A;T	368;370;367	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1019	1021	GGT	371;371;369	G;G;T	371;371;369	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1034	1036	ATG	357;357;355	A;T,C;G	357;356,1;355	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1148	1150	GCA	326;325;322	G,T;C;A,G	325,1;325;321,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1151	1153	ACG	321;323;325	A;CGGGGG,CGGGG;G	320;307,1;324	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1154	1156	GGG	327;327;325	G;G;G	325;325;323	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1157	1159	GTT	323;325;324	G;T,G,C;T,G,C	321;323,1,1;322,1,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1217	1219	GTA	365;361;363	G;T;A	365;361;363	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1256	1258	ACT	345;342;342	A;C;T	345;342;342	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1262	1264	GAT	346;347;347	G;A;T	346;347;347	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1274	1276	CAC	359;361;364	C,A;A;C	358,1;361;364	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	1	SNP	p	G120K	1	.	.	358	360	AAG	739	741	CGG	338;337;336	C,A;G;G,A	337,1;337;335,1	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	1	SNP	p	A121D	1	.	.	361	363	GAC	742	745	CGC	334;334;337	C,A;G;C,A	333,1;334;336,1	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	4162	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1599	318.9	1	SNP	p	D121N	0	.	.	361	363	GAC	742	745	CGC	334;334;337	C,A;G;C,A	333,1;334;336,1	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	13410	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5282	316.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2162	2164	AAT	367;369;369	A;A,C;T	367;368,1;369	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	2040	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1601	159.0	1	SNP	p	V57M	1	.	.	169	171	ATG	773	775	ATG	374;378;383	A;T;G	373;377;382	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
